EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Dietary β-1,3/1,6-Glucan from Baker’s Yeast Supports Upper Respiratory Mucosal Immune Health in Healthy Adults: Evidence from a Randomized, Double-Blind, Placebo-Controlled Trial

Takashi Kanno, Ken-Ichi Ishibashi, Shota Kajiyama, Takanori Ikawa, Taiki Morita, Kenta Murata iD, Shuu Imai, Machiko Nishioka, Yoshiyuki Adachi iD

Nutrients · 18.03.2026 · 18 (6) · 961

DOI: 10.3390/nu18060961 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Nutrients, online erschienen am 18.03.2026. Verfasst von Takashi Kanno und 8 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory for Immunopharmacology of Microbial Products, Tokyo University of Pharmacy and Life Sciences, Hachioji 192-0392, Japan. Hauptthemen laut MEDLINE: Saccharomyces cerevisiae, Immunity, Mucosal, Respiratory Mucosa, Glucans. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kobayashi Pharmaceutical Co., Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objective: Dietary polysaccharides are increasingly recognized as functional nutritional components that support human health through modulation of immune function. However, clinical evidence linking their intake to site-specific upper respiratory mucosal immune health in humans remains limited. This study investigated whether dietary β-1,3/1,6-glucan (SC-BG) from baker’s yeast may support upper respiratory mucosal immune health in healthy adults.

Methods

Following in vitro assays on human dendritic cells (DCs), a randomized, double-blind, placebo-controlled parallel-group trial was performed in healthy adults (18–69 years) who consumed either SC-BG or placebo capsules for 12 weeks in Japan. The primary outcome was circulating DC activation. Secondary outcomes were mucosal immune markers including secretory immunoglobulin A (s-IgA) and lysozymes from site-specific mucosal swabs (posterior oropharyngeal wall/nasopharynx) and salivar, and self-perceived upper respiratory tract symptoms.

Results

SC-BG increased CD80 expression in DCs in vitro. In the clinical trial, 40 participants were randomized (n = 20 per group), and 39 (SC-BG: n = 19, placebo: n = 20) were analyzed. At week 8, the SC-BG group showed higher cDC1 CD80 expression than placebo. SC-BG intake also attenuated declines in s-IgA levels in the posterior oropharyngeal wall and nasopharynx and increased salivary lysozyme concentrations. Participants receiving SC-BG reported fewer cumulative days with upper respiratory tract-related local and systemic symptoms. No test food-related adverse events were observed.

Conclusions

These findings provide preliminary clinical and mechanistic observations suggesting that dietary SC-BG may enhance circulating cDC1 activation and may help support upper respiratory local mucosal immune health in healthy adults, highlighting the potential of dietary polysaccharides as functional nutritional strategies for maintaining immune resilience.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Saccharomyces cerevisiaeImmunity, MucosalRespiratory MucosaGlucansbeta-GlucansHumansAdultDouble-Blind MethodMiddle AgedMaleFemaleAgedYoung AdultAdolescentDendritic CellsJapanImmunonutrition DietDietary Supplements

Stichwörter der Autor:innen

dietary polysaccharidesfunctional polysaccharidehuman healthmucosal immunityrandomized controlled trialβ-1,3/1,6-glucan

Substanzen

Glucansbeta-Glucans

Autor:innen und Institutionen

  • Laboratory for Immunopharmacology of Microbial Products, Tokyo University of Pharmacy and Life Sciences, Hachioji 192-0392, Japan.
  • Laboratory of Host Defense and Responses, Faculty of Nutrition, Kagawa Nutrition University, Sakado 350-0288, Japan.
  • R&D Headquarters, Life Science Research Department, Kobayashi Pharmaceutical Co., Ltd., Ibaraki 567-0057, Japan.

ORCID-Profile: Kenta Murata, Yoshiyuki Adachi

Förderung

  • Kobayashi Pharmaceutical Co., Ltd.

Zitieren

APA

Kanno, T., Ishibashi, K. I., Kajiyama, S., Ikawa, T., Morita, T., Murata, K., Imai, S., Nishioka, M., & Adachi, Y. (2026). Dietary β-1,3/1,6-Glucan from Baker’s Yeast Supports Upper Respiratory Mucosal Immune Health in Healthy Adults: Evidence from a Randomized, Double-Blind, Placebo-Controlled Trial. Nutrients, 18(6), 961. https://doi.org/10.3390/nu18060961

Vancouver

Kanno T, Ishibashi KI, Kajiyama S, Ikawa T, Morita T, Murata K, et al. Dietary β-1,3/1,6-Glucan from Baker’s Yeast Supports Upper Respiratory Mucosal Immune Health in Healthy Adults: Evidence from a Randomized, Double-Blind, Placebo-Controlled Trial. Nutrients. 2026;18(6):961. doi:10.3390/nu18060961

BibTeX
@article{Kanno2026,
  author = {Kanno, Takashi and Ishibashi, Ken-Ichi and Kajiyama, Shota and Ikawa, Takanori and Morita, Taiki and Murata, Kenta and Imai, Shuu and Nishioka, Machiko and Adachi, Yoshiyuki},
  title = {Dietary β-1,3/1,6-Glucan from Baker’s Yeast Supports Upper Respiratory Mucosal Immune Health in Healthy Adults: Evidence from a Randomized, Double-Blind, Placebo-Controlled Trial},
  journal = {Nutrients},
  year = {2026},
  volume = {18},
  number = {6},
  pages = {961},
  doi = {10.3390/nu18060961}
}
Kostenlos starten →